肌萎缩侧索硬化中的脑脊液巨噬细胞生物标志物
该研究采用液相色谱-串联质谱无标记定量法,检测肌萎缩侧索硬化(ALS,n=43)、原发性侧索硬化(PLS,n=6)、健康对照(n=20)及疾病对照(帕金森病n=20、ALS模拟病n=12)的脑脊液蛋白。发现ALS中三种巨噬细胞来源几丁质酶升高,与疾病进展速度及磷酸化神经丝重链相关;高CHIT1与生存期缩短相关(HR 2.84)。
要点
- ALS患者脑脊液CHIT1、CHI3L1、CHI3L2水平升高,CHI3L1在ALS和PLS中均升高。
- 几丁质酶水平与疾病进展速度及pNFH相关,高CHIT1与生存期缩短相关(HR 2.84)。
- 生存模型纳入pNFH后,仅pNFH与生存相关(HR 1.26),提示几丁质酶作用可能部分重叠。
核心结论
- 结果支持巨噬细胞活性在ALS发病机制中的关键作用,为以神经炎症为靶点的ALS治疗提供新的靶点结合与药效动力学生物标志物。
研究设计与样本
- 采用液相色谱-串联质谱无标记定量法,检测纵向队列中ALS患者(n=43)、原发性侧索硬化患者(n=6)、横断面健康对照(n=20)及疾病对照(帕金森病n=20;ALS模拟病n=12)的脑脊液蛋白。
主要发现
- ALS中三种巨噬细胞来源几丁质酶丰度增加:CHIT1、CHI3L1和CHI3L2。
- CHI3L1升高见于ALS和PLS,而CHIT1和CHI3L2水平不同。
- 几丁质酶水平与疾病进展速度相关:CHIT1 r=0.56,p<0.001;CHI3L1 r=0.31,p=0.028;CHI3L2 r=0.29,p=0.044。
- CHIT1、CHI3L1、CHI3L2与pNFH相关:r=0.62,p<0.001;r=0.49,p<0.001;r=0.41,p<0.001。
- 在初始水平低的患者中,CHI3L1随时间升高(梯度=0.005 log丰度单位/月,p=0.001),CHIT1和CHI3L2未升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The neurodegenerative disease, amyotrophic lateral sclerosis (ALS), is a heterogeneous clinical syndrome involving multiple molecular pathways. The development of biomarkers for use in therapeutic trials is a priority. We sought to use a high-throughput proteomic method to identify novel biomarkers in individual cerebrospinal fluid (CSF) samples. METHODS: Liquid chromatography/tandem mass spectrometry with label-free quantification was used to identify CSF proteins using samples from a well-characterized longitudinal cohort comprising patients with ALS (n = 43), the upper motor neuron variant, primary lateral sclerosis (PLS; n = 6), and cross-sectional healthy (n = 20) and disease controls (Parkinsons' disease, n = 20; ALS mimic disorders, n = 12). RESULTS: Three macrophage-derived chitinases showed increased abundance in ALS: chitotriosidase (CHIT1), chitinase-3-like protein 1 (CHI3L1), and chitinase-3-like protein 2 (CHI3L2). Elevated CHI3L1 was common to ALS and PLS, whereas CHIT1 and CHI3L2 levels differed. Chitinase levels correlated with disease progression rate (CHIT1, r = 0.56, p < 0.001; CHI3L1, r = 0.31; p = 0.028; CHI3L2, r = 0.29, p = 0.044). CHIT1, CHI3L1, and CHI3L2 levels correlated with phosphorylated neurofilament heavy chain (pNFH; r = 0.62, p < 0.001; r = 0.49, p < 0.001; r = 0.41, p < 0.001). CHI3L1 levels, but not CHIT1 or CHI3L2, increased over time in those with low initial levels (gradient = 0.005 log abundance units/month, p = 0.001). High CHIT1 was associated with shortened survival (hazard ratio [HR] 2.84; p = 0.009). Inclusion of pNFH in survival models left only an association of pNFH and survival (HR 1.26; p = 0.019). INTERPRETATION: Neuroinflammatory mechanisms have been consistently implicated through various experimental paradigms. These results support a key role for macrophage activity in ALS pathogenesis, offering novel target engagement and pharmacodynamic biomarkers for neuroinflammation-focused ALS therapy. Ann Neurol 2018;83:258-268.
引用
- Thompson AG, Gray E, Thézénas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018. PMID: 29331073. doi:10.1002/ana.25143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。